Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

British Journal of Cancer

Volumn 76, Issue 7, 1997, Pages 917-922

  Niskanen, E ^a,b   Blomqvist, C ^a   Franssila, K ^a   Hietanen, P ^a   Wasenius, V M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

c erb B 2; Cathepsin D; Histological grade; Metastatic breast cancer; P53

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CATHEPSIN D; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; ONCOPROTEIN; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0030847311     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.484     Document Type: Article

References (50)

1. Aas T, Geisler S, Paulsen T, Borresen-Dale AL, Varhaug JL, Lonning PE and Akslen LA (1996) Primary treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer: clinical experience and parameters predicting outcome. Acta Oncol (in press)
2. Allred DC, Clark GM, Elledge R, Fugua SAW, Brown RW, Chamness GC, Osborne CK and McGuire WL (1993) Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
3. Altman DG (1991) Practical Statistics for Research. Chapman and Hall: London, p. 406
4. Barbareschi M, Leonardi E, Mauri FA, Serio G and Palma D (1992) p53 and c-erbB-2 protein expression in breast carcinomas. Ann J Clin Pathol 98: 408-418
5. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS and Altman DG (1988) An immunohistochemical evaluation of c-erbB-2 expression in human breast cancer. Br J Cancer 58: 448-452
6. Bartek (1990) Patterns of expression of the p53 tumor suppressor in human breast cancer tissues and tumors in situ and in vitro. Int J Cancer 46: 839-844
7. Blamey RW and Galea MH (1994) Routine use of adjuvant chemotherapy in node-negative patients with breast cancer is not indicated. In Breast Cancer: Controversies in Management, Wise L and Johnson H. (eds), pp. 359-366. Jr. Futura, Armonk: New York
8. Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K and Helle L (1993) Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: A randomized trial comparing weekly and every-4-week administration. J Clin Oncol 11: 467-473
9. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fugua SA, Killander A and McGuire WL (1990) HER-2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res 50: 4332-4337
10. Cattoretti G, Rilke F, Andreola S, D'Amato L and Delia D (1988) p53 expression in breast cancer. Int J Cancer 41: 178-183
11. Clayton F (1991) Pathological correlates of survival in 378 lymph-node negative infiltrating ductal breast cancers. Mitotic count is the best single predictor. Cancer 68: 1309-1317
12. Cousseus L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seaburgh PH, Lieberman TA, Schlessinger J and Francke V (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132
13. Damstrup L, Andersen J, Kufe DW, Hayes DF and Skovgaard-Poulsen H (1992) Immunocytochemical determination of the estrogen-regulated proteins Mr 24000, Mr 52000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol 3: 71-77
14. Davidoff AM, Humphrey PA, Iglehart JD and Marks JR (1991) Genetic basis for p53 expression in human breast cancer. Proc Natl Acad Sci USA 88: 5006-5010
15. Elledge RM, McGuire WL and Osborne CK (1992) Prognostic factors in breast cancer. Semin Oncol 19: 244-253
16. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Randin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC and Allred DC (1995) Accumulation of p53 protein as possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J Natl Cancer Inst 87: 1254-1256
17. Elston CW (1987) Grading of invasive carcinoma of the breast. In Diagnostic Histopathology of the Breast, Page DL and Anderson TJ (eds), pp. 300-311. Churchill Livingstone: Edinburgh
18. Gilchrist K, Kalsih L, Gould V, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J and Roth JA (1985) Interobserver reproducibility of histopathological features in stage 2 breast cancer. Breast Cancer Res Treat 5: 3-10
19. Hayward JL, Rubens RD, Carbone PP, Henson JC, Kumaoka S and Segaloff A (1977) Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298
20. Heintz NH, Leslie KD, Rogers LA and Howard PL (1990) Amplification of the c-erbB-2 oncogene and prognosis in breast cancer. Arch Pathol Lab Med 114: 160-163
21. Horak E, Smith K and Bromkuy L (1991) Mutant p53, HGF receptor and c-erb-B2 expression in human breast cancer. Oncogene 6: 2277-2284
22. Isola J, Visakorpi T, Holli K und Kallioniemi OP (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114
23. Jacuerner J, Moles JP, Penault-Lorca F, Adelaine J, Torrente M, Vians P, Birngaum D and Theillet C (1994) p53 immunochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 69: 846-852
24. Joensuu H, Toikkanen S and Isola J (1995) Stromal cell cathepsin-D expression and long term survival in breast cancer. Br J Cancer 71: 155-159
25. Klijn JGM, Berns PMJJ, Bontenbal M, Alexieva-Figurch J and Foekens JA (1992) Clinical breast cancer, new developments in selection and endocrine treatment of patients J Steroid Biochem Mol Biol 43: 211-221
26. Klijn JGM, Berns EMJJ, Bontenbal M and Foekens J (1993a) Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treatment Rev 19 (suppl.B): 45-63
27. Klijn JGM, Berns EMJJ and Foekens JA (1993b) Prognostic factor and response to therapy in breast cancer. In Cancer Surveys, Vol. 18, Fentiman IS and Taylor-Papadimitriou J (eds), pp. 165-198. Coldspring Harbor Press: New York
28. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U and Mueller H (1994) Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344: 1648-1649
29. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M and Welsh D (1994) The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69: 409-416
30. Makris A, Powles TJ, Dowsett M and Allred C (1995) p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345: 1181-1182
31. Marx J (1993) How p53 suppresses cell growth. Science 262: 1644-1645
32. Mathieu M-C, Koscielny S, Le Bihan M-L, Spielmann M and Arriagada R (1995) p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345: 1182
33. McDivitt R, Stewart F and Berg J (1968) Tumours of the breast. In Atlas of Tumor Pathology, Firninger HJ (ed.), Armed Forces Institute of Pathology: Washington
34. Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Furye RA and Liu E (1992) Technical report. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 7: 1019-1025
35. O'Donahue AEMA, Poller DN and Bell JA (1995) Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat 33: 137-145
36. Ostrowski JL, Sarvan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJ, Angus B and Horne CH (1991) p53 expression in human breast cancer related to survival and prognostic factors: an immunochemical study. J Pathol 164: 75-81
37. Parkes HC, Lillyrop K, Howell A and Graig RK (1990) c-erbB 2 mRNA expression in human breast tumours: comparison with c-erbB-2 DNA amplification and correlation with prognosis. Br J Cancer 61: 39-45
38. Poller DN, Hutchings CE, Galea MH, Bell JA, Nicholson RA, Elston CW, Blamey RW and Ellis IO (1992) p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erb-B2 protein overexpression and oestrogen receptor. Br J Cancer 66: 583-588
39. Scarff R and Torlini H (1968) Histological Typing of Breast Tumors. WHO: Geneva
40. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER/neu oncogene. Science 235: 177-182
41. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Kaith DE, Levin WJ, Stuart SG, Udove J and Ullrich A (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712
42. Stenkvist B, Bengtsson E, Eriksson O, Jarksans T, Nordin B and Westman-Naeser S (1983) Histopathological grading system of breast cancer classification: reproducibility and clinical significance J Clin Pathol 36: 392-398
43. Tandon AK, Clark GM, Chamness GC, Ullrch A and McGuire WL (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128
44. Tetu B, Brisson J, Coté C, Brisson S, Potvin D and Roberge N (1993) Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 55: 429-435
45. Van de Vivjer MJ, Peterse JL, Mooi WJ, Wisman P, Lonans J, Dalesio O and Nusse R (1988) Neu-protein overexpression in breast cancer. N Engl J Med 319: 1239-1245
46. Varley JM, Swallow JE, Brammer WJ, Whittaker JL and Walker RA (1987) Alterations to either c-erhB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short term prognosis. Oncogene 1: 432-430
47. Walker RA, Gullick WJ and Garley JM (1989) An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 60: 426-429
48. Walker RA, Dearing SJ, Lane DP and Varley JH (1991) Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 165: 203-211
49. Winstanley JHR, Leinster SJ, Cooke TG, Westley BR, Plats-Higgins AM and Rudland DL (1993) Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 67: 767-772
50. Zhou DJ, Ahuja H and Cline MJ (1989) Proto-oncogene ahnormalities in human nreast cancer: c-erbB-2 amplication does not correlate with recurrence of disease. Oncogene 4: 105-108